Search

Your search keyword '"Graham, Barney S."' showing total 1,723 results
Start Over Author "Graham, Barney S."
1,723 results on '"Graham, Barney S."'

401. Determinants of Antibody Response after Recombinant gp160 Boosting in Vaccinia-Naive Volunteers Primed with gp160-Recombinant Vaccinia Virus

Author

National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network, Graham, Barney S., Gorse, Geoffrey J., Schwartz, David H., Keefer, Michael C., McElrath, M. Juliana, Matthews, Thomas J., Wright, Peter F., Belshe, Robert B., Clements, Mary Lou, Dolin, Raphael, Corey, Lawrence, Bolognesi, Dani P., Stablein, Donald M., Esterlitz, Joy R., Hu, Shiu-Lok, and Smith, Gale E.

Published
1994

404. Vaccination of Vaccinia-Naive Adults with Human Immunodeficiency Virus Type 1 gp160 Recombinant Vaccinia Virus in a Blinded, Controlled, Randomized Clinical Trial

Author

AIDS Vaccine Clinical Trails Network, Graham, Barney S., Belshe, Robert B., Clements, Mary Lou, Dolin, Raphael, Corey, Lawrence, Wright, Peter F., Gorse, Geoffrey J., Midthun, Karen, Keefer, Michael C., Roberts, Norbert J., Schwartz, David H., Agosti, Jan M., Fernie, Bruce F., Stablein, Donald M., Montefiori, David C., Lambert, John S., Esterlitz, Joy R., Lawrence, Dale N., and Koff, Wayne C.

Published
1992

405. Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gpl60 Recombinant Vaccinia and Boosting with rgpl60 in Vaccinia-Naive Adults

Author

NIAID AIDS Vaccne Clinical Trails Network, Graham, Barney S., Matthews, Thomas J., Belshe, Robert B., Clements, Mary Lou, Dolin, Raphael, Wright, Peter F., Gorse, Geoffrey J., Schwartz, David H., Keefer, Michael C., Bolognesi, Dani P., Corey, Lawrence, Stablein, Donald M., Esterlitz, Joy R., Hu, Shiu-Lok, Smith, Gale E., Fast, Patricia E., and Koff, Wayne C.

Published
1993

408. Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans.

Author

Grifoni, Alba, Dermody, Terence S1, Grifoni, Alba, Pham, John, Sidney, John, O'Rourke, Patrick H, Paul, Sinu, Peters, Bjoern, Martini, Sheridan R, de Silva, Aruna D, Ricciardi, Michael J, Magnani, Diogo M, Silveira, Cassia GT, Maestri, Alvino, Costa, Priscilla R, de-Oliveira-Pinto, Luzia Maria, de Azeredo, Elzinandes Leal, Damasco, Paulo Vieira, Phillips, Elizabeth, Mallal, Simon, de Silva, Aravinda M, Collins, Matthew, Durbin, Anna, Diehl, Sean A, Cerpas, Cristhiam, Balmaseda, Angel, Kuan, Guillermina, Coloma, Josefina, Harris, Eva, Crowe, James E, Stone, Mars, Norris, Phillip J, Busch, Michael, Vivanco-Cid, Hector, Cox, Josephine, Graham, Barney S, Ledgerwood, Julie E, Turtle, Lance, Solomon, Tom, Kallas, Esper G, Watkins, David I, Weiskopf, Daniela, Sette, Alessandro, Grifoni, Alba, Dermody, Terence S1, Grifoni, Alba, Pham, John, Sidney, John, O'Rourke, Patrick H, Paul, Sinu, Peters, Bjoern, Martini, Sheridan R, de Silva, Aruna D, Ricciardi, Michael J, Magnani, Diogo M, Silveira, Cassia GT, Maestri, Alvino, Costa, Priscilla R, de-Oliveira-Pinto, Luzia Maria, de Azeredo, Elzinandes Leal, Damasco, Paulo Vieira, Phillips, Elizabeth, Mallal, Simon, de Silva, Aravinda M, Collins, Matthew, Durbin, Anna, Diehl, Sean A, Cerpas, Cristhiam, Balmaseda, Angel, Kuan, Guillermina, Coloma, Josefina, Harris, Eva, Crowe, James E, Stone, Mars, Norris, Phillip J, Busch, Michael, Vivanco-Cid, Hector, Cox, Josephine, Graham, Barney S, Ledgerwood, Julie E, Turtle, Lance, Solomon, Tom, Kallas, Esper G, Watkins, David I, Weiskopf, Daniela, and Sette, Alessandro

Abstract

While progress has been made in characterizing humoral immunity to Zika virus (ZIKV) in humans, little is known regarding the corresponding T cell responses to ZIKV. Here, we investigate the kinetics and viral epitopes targeted by T cells responding to ZIKV and address the critical question of whether preexisting dengue virus (DENV) T cell immunity modulates these responses. We find that memory T cell responses elicited by prior infection with DENV or vaccination with tetravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derived peptides. This cross-reactivity is explained by the sequence similarity of the two viruses, as the ZIKV peptides recognized by DENV-elicited memory T cells are identical or highly conserved in DENV and ZIKV. DENV exposure prior to ZIKV infection also influences the timing and magnitude of the T cell response. ZIKV-reactive T cells in the acute phase of infection are detected earlier and in greater magnitude in DENV-immune patients. Conversely, the frequency of ZIKV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors but declines in DENV-preexposed donors, compatible with more efficient control of ZIKV replication and/or clearance of ZIKV antigen. The quality of responses is also influenced by previous DENV exposure, and ZIKV-specific CD8 T cells from DENV-preexposed donors selectively upregulated granzyme B and PD1, unlike DENV-naive donors. Finally, we discovered that ZIKV structural proteins (E, prM, and C) are major targets of both the CD4 and CD8 T cell responses, whereas DENV T cell epitopes are found primarily in nonstructural proteins.IMPORTANCE The issue of potential ZIKV and DENV cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of great relevance, as the two viruses often cocirculate and Zika virus has been spreading in geographical regions where DENV is endemic or hyperendemic. Our data show that memory T cell responses elicited by prior infection wit

Published
2017

409. Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report

Author

Ledgerwood, Julie E, Dezure, Adam D, Stanley, Daphne A, Novik, Laura, Enama, Mary E, Berkowitz, Nina M, Hu, Zonghui, Joshi, Gyan, Ploquin, Aurélie, Sitar, Sandra, Gordon, Ingelise J, Plummer, Sarah A, Holman, LaSonji A, Hendel, Cynthia S, Yamshchikov, Galina, Roman, Francois, Colloca, Stefano, Cortese, Riccardo, Bailer, Robert T, Schwartz, Richard M, Roederer, Mario, Mascola, John R, Koup, Richard A, Sullivan, Nancy J, Graham, Barney S., NICOSIA, Alfredo, Ledgerwood, Julie E, Dezure, Adam D, Stanley, Daphne A, Novik, Laura, Enama, Mary E, Berkowitz, Nina M, Hu, Zonghui, Joshi, Gyan, Ploquin, Aurélie, Sitar, Sandra, Gordon, Ingelise J, Plummer, Sarah A, Holman, LaSonji A, Hendel, Cynthia S, Yamshchikov, Galina, Roman, Francoi, Nicosia, Alfredo, Colloca, Stefano, Cortese, Riccardo, Bailer, Robert T, Schwartz, Richard M, Roederer, Mario, Mascola, John R, Koup, Richard A, Sullivan, Nancy J, and Graham, Barney S.

Abstract

Background The unprecedented 2014 epidemic of Ebola virus disease (EVD) has prompted an international response to accelerate the availability of a preventive vaccine. A replication-defective recombinant chimpanzee adenovirus type 3-vectored ebolavirus vaccine (cAd3-EBO), encoding the glycoprotein from Zaire and Sudan species that offers protection in the nonhuman primate model, was rapidly advanced into phase 1 clinical evaluation. Methods We conducted a phase 1, dose-escalation, open-label trial of cAd3-EBO. Twenty healthy adults, in sequentially enrolled groups of 10 each, received vaccination intramuscularly in doses of 2×10(10) particle units or 2×10(11) particle units. Primary and secondary end points related to safety and immunogenicity were assessed throughout the first 4 weeks after vaccination. Results In this small study, no safety concerns were identified; however, transient fever developed within 1 day after vaccination in two participants who had received the 2×10(11) particle-unit dose. Glycoprotein-specific antibodies were induced in all 20 participants; the titers were of greater magnitude in the group that received the 2×10(11) particle-unit dose than in the group that received the 2×10(10) particle-unit dose (geometric mean titer against the Zaire antigen, 2037 vs. 331; P=0.001). Glycoprotein-specific T-cell responses were more frequent among those who received the 2x10(11) particle-unit dose than among those who received the 2×10(10) particle-unit dose, with a CD4 response in 10 of 10 participants versus 3 of 10 participants (P=0.004) and a CD8 response in 7 of 10 participants versus 2 of 10 participants (P=0.07). Conclusions Reactogenicity and immune responses to cAd3-EBO vaccine were dose-dependent. At the 2×10(11) particle-unit dose, glycoprotein Zaire-specific antibody responses were in the range reported to be associated with vaccine-induced protective immunity in challenge studies involving nonhuman primates. Clinical trials assessing cAd3-EBO are ongoing. (Funded by the Intramural Research Program of the National Institutes of Health; VRC 207 ClinicalTrials.gov number, NCT02231866 .).

Published
2014

410. Quadrivalent influenza nanoparticle vaccines induce broad protection

Author

Boyoglu-Barnum, Seyhan, Ellis, Daniel, Gillespie, Rebecca A., Hutchinson, Geoffrey B., Park, Young-Jun, Moin, Syed M., Acton, Oliver J., Ravichandran, Rashmi, Murphy, Mike, Pettie, Deleah, Matheson, Nick, Carter, Lauren, Creanga, Adrian, Watson, Michael J., Kephart, Sally, Ataca, Sila, Vaile, John R., Ueda, George, Crank, Michelle C., Stewart, Lance, Lee, Kelly K., Guttman, Miklos, Baker, David, Mascola, John R., Veesler, David, Graham, Barney S., King, Neil P., and Kanekiyo, Masaru

Abstract

Influenza vaccines that confer broad and durable protection against diverse viral strains would have a major effect on global health, as they would lessen the need for annual vaccine reformulation and immunization1. Here we show that computationally designed, two-component nanoparticle immunogens2induce potently neutralizing and broadly protective antibody responses against a wide variety of influenza viruses. The nanoparticle immunogens contain 20 haemagglutinin glycoprotein trimers in an ordered array, and their assembly in vitro enables the precisely controlled co-display of multiple distinct haemagglutinin proteins in defined ratios. Nanoparticle immunogens that co-display the four haemagglutinins of licensed quadrivalent influenza vaccines elicited antibody responses in several animal models against vaccine-matched strains that were equivalent to or better than commercial quadrivalent influenza vaccines, and simultaneously induced broadly protective antibody responses to heterologous viruses by targeting the subdominant yet conserved haemagglutinin stem. The combination of potent receptor-blocking and cross-reactive stem-directed antibodies induced by the nanoparticle immunogens makes them attractive candidates for a supraseasonal influenza vaccine candidate with the potential to replace conventional seasonal vaccines3.

Published
2021
Full Text
View/download PDF

411. ZIKV-specific CD8 T cell immunity in humans is affected by DENV pre-exposure

Author

Alba, Pham, John, Peters, Bjorn, De-Oliveira-Pinto, Maria Luzia, Silva, Aravinda, Durbin, Anna, Diehl, Sean A., Harris, Eva, Crowe, James, Busch, Micheal, Vivanco-Cid, Hector, Graham, Barney S., Turtle, Lance, Kallas, Esper, Watkins, David, Weiskopf, Daniela, and Sette, Alessandro

Subjects
Immunology, Immunology and Allergy
Abstract

Several studies have characterized humoral immunity to Zika virus (ZIKV) in humans but little is known regarding the corresponding T cell responses to ZIKV. In this study we sought to investigate the ZIKV-specific T cell response in terms of kinetics and viral epitopes targeted and whether pre-existing dengue virus (DENV) T cell immunity can affect these responses. Our results shows that memory T cell responses elicited by prior infection with DENV infection or vaccination recognize ZIKV-derived peptides. The cross-reactive response is explained by the sequence similarity of the two viruses, as the ZIKV peptides recognized are either identical or highly conserved between DENV and ZIKV. In addition, DENV exposure also influences the timing and magnitude of the ZIKV-specific T cell response. In the acute phase of infection, ZIKV-reactive T cells are detected earlier and in greater magnitude than those in DENV pre-exposed patients. Conversely, while the frequency of ZIKV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors, it declines in DENV pre-exposed donors. In addition, ZIKV-specific CD8 T cells form DENV pre-exposed donors selectively up-regulated granzyme B and PD1, as compared to DENV-naïve donors. These results overall suggest a more efficient control of ZIKV replication and/or clearance of ZIKV antigen in patients with previous DENV exposure. Finally, when we focused on the viral epitopes targeted by DENV naïve donors, ZIKV structural proteins (E, prM and C) are major targets of CD8 T cell responses, whereas DENV pre-exposed individuals skew the T cell epitopes primarily in nonstructural proteins.

Published
2018

412. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein

Author

Tian, Daiyin, primary, Battles, Michael B., additional, Moin, Syed M., additional, Chen, Man, additional, Modjarrad, Kayvon, additional, Kumar, Azad, additional, Kanekiyo, Masaru, additional, Graepel, Kevin W., additional, Taher, Noor M., additional, Hotard, Anne L., additional, Moore, Martin L., additional, Zhao, Min, additional, Zheng, Zi-Zheng, additional, Xia, Ning-Shao, additional, McLellan, Jason S., additional, and Graham, Barney S., additional

Published
2017
Full Text
View/download PDF

413. Correction: Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state

Author

Rossey, Iebe, primary, Gilman, Morgan S. A., additional, Kabeche, Stephanie C., additional, Sedeyn, Koen, additional, Wrapp, Daniel, additional, Kanekiyo, Masaru, additional, Chen, Man, additional, Mas, Vicente, additional, Spitaels, Jan, additional, Melero, José A., additional, Graham, Barney S., additional, Schepens, Bert, additional, McLellan, Jason S., additional, and Saelens, Xavier, additional

Published
2017
Full Text
View/download PDF

414. Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120

Author

deCamp, Allan C., primary, Rolland, Morgane, additional, Edlefsen, Paul T., additional, Sanders-Buell, Eric, additional, Hall, Breana, additional, Magaret, Craig A., additional, Fiore-Gartland, Andrew J., additional, Juraska, Michal, additional, Carpp, Lindsay N., additional, Karuna, Shelly T., additional, Bose, Meera, additional, LePore, Steven, additional, Miller, Shana, additional, O'Sullivan, Annemarie, additional, Poltavee, Kultida, additional, Bai, Hongjun, additional, Dommaraju, Kalpana, additional, Zhao, Hong, additional, Wong, Kim, additional, Chen, Lennie, additional, Ahmed, Hasan, additional, Goodman, Derrick, additional, Tay, Matthew Z., additional, Gottardo, Raphael, additional, Koup, Richard A., additional, Bailer, Robert, additional, Mascola, John R., additional, Graham, Barney S., additional, Roederer, Mario, additional, O’Connell, Robert J., additional, Michael, Nelson L., additional, Robb, Merlin L., additional, Adams, Elizabeth, additional, D’Souza, Patricia, additional, Kublin, James, additional, Corey, Lawrence, additional, Geraghty, Daniel E., additional, Frahm, Nicole, additional, Tomaras, Georgia D., additional, McElrath, M. Juliana, additional, Frenkel, Lisa, additional, Styrchak, Sheila, additional, Tovanabutra, Sodsai, additional, Sobieszczyk, Magdalena E., additional, Hammer, Scott M., additional, Kim, Jerome H., additional, Mullins, James I., additional, and Gilbert, Peter B., additional

Published
2017
Full Text
View/download PDF

415. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F

Author

Liu, Xiang, primary, Liang, Bo, additional, Ngwuta, Joan, additional, Liu, Xueqiao, additional, Surman, Sonja, additional, Lingemann, Matthias, additional, Kwong, Peter D., additional, Graham, Barney S., additional, Collins, Peter L., additional, and Munir, Shirin, additional

Published
2017
Full Text
View/download PDF

416. HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques

Author

Han, Qifeng, primary, Williams, Wilton B., additional, Saunders, Kevin O., additional, Seaton, Kelly E., additional, Wiehe, Kevin J., additional, Vandergrift, Nathan, additional, Von Holle, Tarra A., additional, Trama, Ashley M., additional, Parks, Robert J., additional, Luo, Kan, additional, Gurley, Thaddeus C., additional, Kepler, Thomas B., additional, Marshall, Dawn J., additional, Montefiori, David C., additional, Sutherland, Laura L., additional, Alam, Munir S., additional, Whitesides, John F., additional, Bowman, Cindy M., additional, Permar, Sallie R., additional, Graham, Barney S., additional, Mascola, John R., additional, Seed, Patrick C., additional, Van Rompay, Koen K. A., additional, Tomaras, Georgia D., additional, Moody, M. Anthony, additional, and Haynes, Barton F., additional

Published
2017
Full Text
View/download PDF

417. Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus

Author

Sastry, Mallika, primary, Zhang, Baoshan, additional, Chen, Man, additional, Joyce, M. Gordon, additional, Kong, Wing-Pui, additional, Chuang, Gwo-Yu, additional, Ko, Kiyoon, additional, Kumar, Azad, additional, Silacci, Chiara, additional, Thom, Michelle, additional, Salazar, Andres M., additional, Corti, Davide, additional, Lanzavecchia, Antonio, additional, Taylor, Geraldine, additional, Mascola, John R., additional, Graham, Barney S., additional, and Kwong, Peter D., additional

Published
2017
Full Text
View/download PDF

418. A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage

Author

Shan, Chao, primary, Muruato, Antonio E., additional, Jagger, Brett W., additional, Richner, Justin, additional, Nunes, Bruno T. D., additional, Medeiros, Daniele B. A., additional, Xie, Xuping, additional, Nunes, Jannyce G. C., additional, Morabito, Kaitlyn M., additional, Kong, Wing-Pui, additional, Pierson, Theodore C., additional, Barrett, Alan D., additional, Weaver, Scott C., additional, Rossi, Shannan L., additional, Vasconcelos, Pedro F. C., additional, Graham, Barney S., additional, Diamond, Michael S., additional, and Shi, Pei-Yong, additional

Published
2017
Full Text
View/download PDF

419. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Author

Pallesen, Jesper, primary, Wang, Nianshuang, additional, Corbett, Kizzmekia S., additional, Wrapp, Daniel, additional, Kirchdoerfer, Robert N., additional, Turner, Hannah L., additional, Cottrell, Christopher A., additional, Becker, Michelle M., additional, Wang, Lingshu, additional, Shi, Wei, additional, Kong, Wing-Pui, additional, Andres, Erica L., additional, Kettenbach, Arminja N., additional, Denison, Mark R., additional, Chappell, James D., additional, Graham, Barney S., additional, Ward, Andrew B., additional, and McLellan, Jason S., additional

Published
2017
Full Text
View/download PDF

420. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab

Author

Zhao, Min, primary, Zheng, Zi-Zheng, additional, Chen, Man, additional, Modjarrad, Kayvon, additional, Zhang, Wei, additional, Zhan, Lu-Ting, additional, Cao, Jian-Li, additional, Sun, Yong-Peng, additional, McLellan, Jason S., additional, Graham, Barney S., additional, and Xia, Ning-Shao, additional

Published
2017
Full Text
View/download PDF

421. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate

Author

Liang, Bo, primary, Ngwuta, Joan O., additional, Surman, Sonja, additional, Kabatova, Barbora, additional, Liu, Xiang, additional, Lingemann, Matthias, additional, Liu, Xueqiao, additional, Yang, Lijuan, additional, Herbert, Richard, additional, Swerczek, Joanna, additional, Chen, Man, additional, Moin, Syed M., additional, Kumar, Azad, additional, McLellan, Jason S., additional, Kwong, Peter D., additional, Graham, Barney S., additional, Collins, Peter L., additional, and Munir, Shirin, additional

Published
2017
Full Text
View/download PDF

422. Preferential induction of cross-group influenza A hemagglutinin stem–specific memory B cells after H7N9 immunization in humans

Author

Andrews, Sarah F., primary, Joyce, M. Gordon, additional, Chambers, Michael J., additional, Gillespie, Rebecca A., additional, Kanekiyo, Masaru, additional, Leung, Kwanyee, additional, Yang, Eun Sung, additional, Tsybovsky, Yaroslav, additional, Wheatley, Adam K., additional, Crank, Michelle C., additional, Boyington, Jeffrey C., additional, Prabhakaran, Madhu S., additional, Narpala, Sandeep R., additional, Chen, Xuejun, additional, Bailer, Robert T., additional, Chen, Grace, additional, Coates, Emily, additional, Kwong, Peter D., additional, Koup, Richard A., additional, Mascola, John R., additional, Graham, Barney S., additional, Ledgerwood, Julie E., additional, and McDermott, Adrian B., additional

Published
2017
Full Text
View/download PDF

424. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

Author

DeZure, Adam D., primary, Coates, Emily E., additional, Hu, Zonghui, additional, Yamshchikov, Galina V., additional, Zephir, Kathryn L., additional, Enama, Mary E., additional, Plummer, Sarah H., additional, Gordon, Ingelise J., additional, Kaltovich, Florence, additional, Andrews, Sarah, additional, McDermott, Adrian, additional, Crank, Michelle C., additional, Koup, Richard A, additional, Schwartz, Richard M., additional, Bailer, Robert T., additional, Sun, Xiangjie, additional, Mascola, John R., additional, Tumpey, Terrence M., additional, Graham, Barney S., additional, and Ledgerwood, Julie E., additional

Published
2017
Full Text
View/download PDF

425. Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses

Author

Coates, Emily E., primary, Costner, Pamela J., additional, Nason, Martha C., additional, Herrin, Douglas M., additional, Conant, Shielah, additional, Herscovitch, Peter, additional, Sarwar, Uzma N., additional, Holman, Lasonji, additional, Mitchell, Jillian, additional, Yamshchikov, Galina, additional, Koup, Richard A., additional, Graham, Barney S., additional, Millo, Corina M., additional, and Ledgerwood, Julie E., additional

Published
2017
Full Text
View/download PDF

427. Chimpanzee Adenovirus Vector Ebola Vaccine

Author

Ledgerwood, Julie E., primary, DeZure, Adam D., additional, Stanley, Daphne A., additional, Coates, Emily E., additional, Novik, Laura, additional, Enama, Mary E., additional, Berkowitz, Nina M., additional, Hu, Zonghui, additional, Joshi, Gyan, additional, Ploquin, Aurélie, additional, Sitar, Sandra, additional, Gordon, Ingelise J., additional, Plummer, Sarah A., additional, Holman, LaSonji A., additional, Hendel, Cynthia S., additional, Yamshchikov, Galina, additional, Roman, Francois, additional, Nicosia, Alfredo, additional, Colloca, Stefano, additional, Cortese, Riccardo, additional, Bailer, Robert T., additional, Schwartz, Richard M., additional, Roederer, Mario, additional, Mascola, John R., additional, Koup, Richard A., additional, Sullivan, Nancy J., additional, and Graham, Barney S., additional

Published
2017
Full Text
View/download PDF

428. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

Author

Lyke, Kirsten E., primary, Ishizuka, Andrew S., additional, Berry, Andrea A., additional, Chakravarty, Sumana, additional, DeZure, Adam, additional, Enama, Mary E., additional, James, Eric R., additional, Billingsley, Peter F., additional, Gunasekera, Anusha, additional, Manoj, Anita, additional, Li, Minglin, additional, Ruben, Adam J., additional, Li, Tao, additional, Eappen, Abraham G., additional, Stafford, Richard E., additional, KC, Natasha, additional, Murshedkar, Tooba, additional, Mendoza, Floreliz H., additional, Gordon, Ingelise J., additional, Zephir, Kathryn L., additional, Holman, LaSonji A., additional, Plummer, Sarah H., additional, Hendel, Cynthia S., additional, Novik, Laura, additional, Costner, Pamela J. M., additional, Saunders, Jamie G., additional, Berkowitz, Nina M., additional, Flynn, Barbara J., additional, Nason, Martha C., additional, Garver, Lindsay S., additional, Laurens, Matthew B., additional, Plowe, Christopher V., additional, Richie, Thomas L., additional, Graham, Barney S., additional, Roederer, Mario, additional, Sim, B. Kim Lee, additional, Ledgerwood, Julie E., additional, Hoffman, Stephen L., additional, and Seder, Robert A., additional

Published
2017
Full Text
View/download PDF

429. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state

Author

Rossey, Iebe, primary, Gilman, Morgan S. A., additional, Kabeche, Stephanie C., additional, Sedeyn, Koen, additional, Wrapp, Daniel, additional, Kanekiyo, Masaru, additional, Chen, Man, additional, Mas, Vicente, additional, Spitaels, Jan, additional, Melero, José A., additional, Graham, Barney S., additional, Schepens, Bert, additional, McLellan, Jason S., additional, and Saelens, Xavier, additional

Published
2017
Full Text
View/download PDF

430. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

Author

Janes, Holly E., primary, Cohen, Kristen W., additional, Frahm, Nicole, additional, De Rosa, Stephen C., additional, Sanchez, Brittany, additional, Hural, John, additional, Magaret, Craig A., additional, Karuna, Shelly, additional, Bentley, Carter, additional, Gottardo, Raphael, additional, Finak, Greg, additional, Grove, Douglas, additional, Shen, Mingchao, additional, Graham, Barney S., additional, Koup, Richard A., additional, Mulligan, Mark J., additional, Koblin, Beryl, additional, Buchbinder, Susan P., additional, Keefer, Michael C., additional, Adams, Elizabeth, additional, Anude, Chuka, additional, Corey, Lawrence, additional, Sobieszczyk, Magdalena, additional, Hammer, Scott M., additional, Gilbert, Peter B., additional, and McElrath, M. Juliana, additional

Published
2017
Full Text
View/download PDF

431. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Author

Pardi, Norbert, primary, Hogan, Michael J., additional, Pelc, Rebecca S., additional, Muramatsu, Hiromi, additional, Andersen, Hanne, additional, DeMaso, Christina R., additional, Dowd, Kimberly A., additional, Sutherland, Laura L., additional, Scearce, Richard M., additional, Parks, Robert, additional, Wagner, Wendeline, additional, Granados, Alex, additional, Greenhouse, Jack, additional, Walker, Michelle, additional, Willis, Elinor, additional, Yu, Jae-Sung, additional, McGee, Charles E., additional, Sempowski, Gregory D., additional, Mui, Barbara L., additional, Tam, Ying K., additional, Huang, Yan-Jang, additional, Vanlandingham, Dana, additional, Holmes, Veronica M., additional, Balachandran, Harikrishnan, additional, Sahu, Sujata, additional, Lifton, Michelle, additional, Higgs, Stephen, additional, Hensley, Scott E., additional, Madden, Thomas D., additional, Hope, Michael J., additional, Karikó, Katalin, additional, Santra, Sampa, additional, Graham, Barney S., additional, Lewis, Mark G., additional, Pierson, Theodore C., additional, Haynes, Barton F., additional, and Weissman, Drew, additional

Published
2017
Full Text
View/download PDF

432. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

Author

Regules, Jason A., primary, Beigel, John H., additional, Paolino, Kristopher M., additional, Voell, Jocelyn, additional, Castellano, Amy R., additional, Hu, Zonghui, additional, Muñoz, Paula, additional, Moon, James E., additional, Ruck, Richard C., additional, Bennett, Jason W., additional, Twomey, Patrick S., additional, Gutiérrez, Ramiro L., additional, Remich, Shon A., additional, Hack, Holly R., additional, Wisniewski, Meagan L., additional, Josleyn, Matthew D., additional, Kwilas, Steven A., additional, Van Deusen, Nicole, additional, Mbaya, Olivier Tshiani, additional, Zhou, Yan, additional, Stanley, Daphne A., additional, Jing, Wang, additional, Smith, Kirsten S., additional, Shi, Meng, additional, Ledgerwood, Julie E., additional, Graham, Barney S., additional, Sullivan, Nancy J., additional, Jagodzinski, Linda L., additional, Peel, Sheila A., additional, Alimonti, Judie B., additional, Hooper, Jay W., additional, Silvera, Peter M., additional, Martin, Brian K., additional, Monath, Thomas P., additional, Ramsey, W. Jay, additional, Link, Charles J., additional, Lane, H. Clifford, additional, Michael, Nelson L., additional, Davey, Richard T., additional, and Thomas, Stephen J., additional

Published
2017
Full Text
View/download PDF

433. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Author

Gilbert, Peter B, primary, Juraska, Michal, additional, deCamp, Allan C., additional, Karuna, Shelly, additional, Edupuganti, Srilatha, additional, Mgodi, Nyaradzo, additional, Donnell, Deborah J, additional, Bentley, Carter, additional, Sista, Nirupama, additional, Andrew, Philip, additional, Isaacs, Abby, additional, Huang, Yunda, additional, Zhang, Lily, additional, Capparelli, Edmund, additional, Kochar, Nidhi, additional, Wang, Jing, additional, Eshleman, Susan H, additional, Mayer, Kenneth H, additional, Magaret, Craig A, additional, Hural, John, additional, Kublin, James G, additional, Gray, Glenda, additional, Montefiori, David C, additional, Gomez, Margarita M, additional, Burns, David N, additional, McElrath, Julie, additional, Ledgerwood, Julie, additional, Graham, Barney S, additional, Mascola, John R, additional, Cohen, Myron, additional, and Corey, Lawrence, additional

Published
2017
Full Text
View/download PDF

435. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors

Author

Gilman, Morgan S. A., primary, Castellanos, Carlos A., additional, Chen, Man, additional, Ngwuta, Joan O., additional, Goodwin, Eileen, additional, Moin, Syed M., additional, Mas, Vicente, additional, Melero, José A., additional, Wright, Peter F., additional, Graham, Barney S., additional, McLellan, Jason S., additional, and Walker, Laura M., additional

Published
2016
Full Text
View/download PDF

436. A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation

Author

Stobart, Christopher C., primary, Rostad, Christina A., additional, Ke, Zunlong, additional, Dillard, Rebecca S., additional, Hampton, Cheri M., additional, Strauss, Joshua D., additional, Yi, Hong, additional, Hotard, Anne L., additional, Meng, Jia, additional, Pickles, Raymond J., additional, Sakamoto, Kaori, additional, Lee, Sujin, additional, Currier, Michael G., additional, Moin, Syed M., additional, Graham, Barney S., additional, Boukhvalova, Marina S., additional, Gilbert, Brian E., additional, Blanco, Jorge C. G., additional, Piedra, Pedro A., additional, Wright, Elizabeth R., additional, and Moore, Martin L., additional

Published
2016
Full Text
View/download PDF

439. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant- Level Meta-Analysis of Randomized Trial

Author

Huang, Yunda, Follmann, Dean, Nason, Martha, Zhang, Lily, Huang, Ying, Mehrotra, Devan V., Moodie, Zoe, Metch, Barbara, Janes, Holly, Keefer, Michael C., Churchyard, Gavin, Robb, Merlin L., Fast, Patricia E., Duerr, Ann, McElrath, M. Juliana, Corey, Lawrence, Mascola, John R., Graham, Barney S., Sobieszczyk, Magdalena E., Kublin, James G., Hammer, Scott M., Robertson, Michael, Gray, Glenda E., Buchbinder, Susan P., and Gilbert, Peter B.

Subjects
Public health, Clinical trials, Epidemiology, Medicine, HIV infections--Epidemiology, Medical policy, HIV-positive persons, AIDS vaccines
Abstract

Background Three phase 2b, double-blind, placebo-controlled, randomized efficacy trials have tested recombinant Adenovirus serotype-5 (rAd5)-vector preventive HIV-1 vaccines: MRKAd5 HIV-1 gag/pol/nef in Step and Phambili, and DNA/rAd5 HIV-1 env/gag/pol in HVTN505. Due to efficacy futility observed at the first interim analysis in Step and HVTN505, participants of all three studies were unblinded to their vaccination assignments during the study but continued follow–up. Rigorous meta-analysis can provide crucial information to advise the future utility of rAd5-vector vaccines. Methods We included participant-level data from all three efficacy trials, and three Phase 1–2 trials evaluating the HVTN505 vaccine regimen. We predefined two co-primary analysis cohorts for assessing the vaccine effect on HIV-1 acquisition. The modified-intention-to-treat (MITT) cohort included all randomly assigned participants HIV-1 uninfected at study entry, who received at least the first vaccine/placebo, and the Ad5 cohort included MITT participants who received at least one dose of rAd5-HIV vaccine or rAd5-placebo. Multivariable Cox regression models were used to estimate hazard ratios (HRs) of HIV-1 infection (vaccine vs. placebo) and evaluate HR variation across vaccine regimens, time since vaccination, and subgroups using interaction tests. Findings Results are similar for the MITT and Ad5 cohorts; we summarize MITT cohort results. Pooled across the efficacy trials, over all follow-up time 403 (n = 224 vaccine; n = 179 placebo) of 6266 MITT participants acquired HIV-1, with a non-significantly higher incidence in vaccine recipients (HR 1.21, 95% CI 0.99–1.48, P = 0.06). The HRs significantly differed by vaccine regimen (interaction P = 0.03; MRKAd5 HR 1.41, 95% CI 1.11–1.78, P = 0.005 vs. DNA/rAd5 HR 0.88, 95% CI 0.61–1.26, P = 0.48). Results were similar when including the Phase 1–2 trials. Exploratory analyses based on the efficacy trials supported that the MRKAd5 vaccine-increased risk was concentrated in Ad5-positive or uncircumcised men early in follow-up, and in Ad5-negative or circumcised men later. Overall, MRKAd5 vaccine-increased risk was evident across subgroups except in circumcised Ad5-negative men (HR 0.97, 95% CI 0.58−1.63, P = 0.91); there was little evidence that the DNA/rAd5 vaccine, that was tested in this subgroup, increased risk (HR 0.88, 95% CI 0.61–1.26, P = 0.48). When restricting the analysis of Step and Phambili to follow-up time before unblinding, 114 (n = 65 vaccine; n = 49 placebo) of 3770 MITT participants acquired HIV-1, with a non-significantly higher incidence in MRKAd5 vaccine recipients (HR 1.30, 95% CI 0.89–1.14, P = 0.18). Interpretation and Significance The data support increased risk of HIV-1 infection by MRKAd5 over all follow-up time, but do not support increased risk of HIV-1 infection by DNA/rAd5. This study provides a rationale for including monitoring plans enabling detection of increased susceptibility to infection in HIV-1 at-risk populations.

Published
2015
Full Text
View/download PDF

440. Animal models for COVID-19

Author

Muñoz-Fontela, César, Dowling, William E., Funnell, Simon G. P., Gsell, Pierre-S., Riveros-Balta, A. Ximena, Albrecht, Randy A., Andersen, Hanne, Baric, Ralph S., Carroll, Miles W., Cavaleri, Marco, Qin, Chuan, Crozier, Ian, Dallmeier, Kai, de Waal, Leon, de Wit, Emmie, Delang, Leen, Dohm, Erik, Duprex, W. Paul, Falzarano, Darryl, Finch, Courtney L., Frieman, Matthew B., Graham, Barney S., Gralinski, Lisa E., Guilfoyle, Kate, Haagmans, Bart L., Hamilton, Geraldine A., Hartman, Amy L., Herfst, Sander, Kaptein, Suzanne J. F., Klimstra, William B., Knezevic, Ivana, Krause, Philip R., Kuhn, Jens H., Le Grand, Roger, Lewis, Mark G., Liu, Wen-Chun, Maisonnasse, Pauline, McElroy, Anita K., Munster, Vincent, Oreshkova, Nadia, Rasmussen, Angela L., Rocha-Pereira, Joana, Rockx, Barry, Rodríguez, Estefanía, Rogers, Thomas F., Salguero, Francisco J., Schotsaert, Michael, Stittelaar, Koert J., Thibaut, Hendrik Jan, Tseng, Chien-Te, Vergara-Alert, Júlia, Beer, Martin, Brasel, Trevor, Chan, Jasper F. W., García-Sastre, Adolfo, Neyts, Johan, Perlman, Stanley, Reed, Douglas S., Richt, Juergen A., Roy, Chad J., Segalés, Joaquim, Vasan, Seshadri S., Henao-Restrepo, Ana María, and Barouch, Dan H.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (first detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and has caused more than 950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World Health Organization (WHO) assembled an international panel to develop animal models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. Here we summarize the findings to date and provides relevant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19.

Published
2020
Full Text
View/download PDF

441. Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial.

Author

Kallas, Esper G., Grunenberg, Nicole A., Yu, Chenchen, Manso, Bryce, Pantaleo, Giuseppe, Casapia, Martin, Baden, Lindsey R., Valencia, Javier, Sobieszczyk, Magdalena, Van Tieu, Hong, Allen, Mary, Hural, John, Graham, Barney S., Kublin, James, Gilbert, Peter B., Corey, Lawrence, Goepfert, Paul A., McElrath, M. Juliana, Johnson, R. Paul, and Huang, Yunda

Subjects
AIDS vaccines, RANDOMIZED response, VACCINE effectiveness, INTRAMUSCULAR injections, VIRAL replication, T cells, IMMUNE response, INTERLEUKIN-21
Abstract

Troublesome T cells: Many HIV vaccines aim to generate robust T cell responses, but two new studies show that this is not always straightforward. Chamcha et al. analyzed data from several nonhuman primate vaccine studies with SIV/SHIV challenges and discovered that achieving a certain threshold of vaccine-induced IFN-γ+ CD4 T cells lowered vaccine efficacy, possibly by providing target cells for the virus. Kallas et al. vaccinated people with HIV Gag/Pol alone or with Env to see whether antigenic competition could interfere with CD4 T cell responses; lower responses to Gag/Pol were detected when Env was also administered, indicating that including multiple antigens in a vaccine may preclude maximal T cell responses. Together, these studies highlight how we must tread carefully on the path to an effective HIV vaccine. T cell responses have been implicated in reduced risk of HIV acquisition in uninfected persons and control of viral replication in HIV-infected individuals. HIV Gag-specific T cells have been predominantly associated with post-infection control, whereas Env antigens are the target for protective antibodies; therefore, inclusion of both antigens is common in HIV vaccine design. However, inclusion of multiple antigens may provoke antigenic competition, reducing the potential effectiveness of the vaccine. HVTN 084 was a randomized, multicenter, double-blind phase 1 trial to investigate whether adding Env to a Gag/Pol vaccine decreases the magnitude or breadth of Gag/Pol-specific T cell responses. Fifty volunteers each received one intramuscular injection of 1 × 1010 particle units (PU) of rAd5 Gag/Pol and EnvA/B/C (3:1:1:1 mixture) or 5 × 109 PU of rAd5 Gag/Pol. CD4+ T cell responses to Gag/Pol measured 4 weeks after vaccination by cytokine expression were significantly higher in the group vaccinated without Env, whereas CD8+ T cell responses did not differ significantly between the two groups. Mapping of individual epitopes revealed greater breadth of the Gag/Pol-specific T cell response in the absence of Env compared to Env coimmunization. Addition of an Env component to a Gag/Pol vaccine led to reduced Gag/Pol CD4+ T cell response rate and magnitude as well as reduced epitope breadth, confirming the presence of antigenic competition. Therefore, T cell–based vaccine strategies should aim at choosing a minimalist set of antigens to reduce interference of individual vaccine components with the induction of the maximally achievable immune response. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

442. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.

Author

Carter, Cristina, Houser, Katherine V., Yamshchikov, Galina V., Bellamy, Abbie R., May, Jeanine, Enama, Mary E., Sarwar, Uzma, Larkin, Brenda, Bailer, Robert T., Koup, Richard, Chen, Grace L., Patel, Shital M., Winokur, Patricia, Belshe, Robert, Dekker, Cornelia L., Graham, Barney S., Ledgerwood, Julie E., and null, null

Subjects
DNA vaccines, SEASONAL influenza, VACCINES, CLINICAL trials, INFLUENZA vaccines
Abstract

Background: Seasonal influenza results in significant morbidity and mortality worldwide, but the currently licensed inactivated vaccines generally have low vaccine efficacies and could be improved. In this phase 1 clinical trial, we compared seasonal influenza vaccine regimens with different priming strategies, prime-boost intervals, and administration routes to determine the impact of these variables on the resulting antibody response. Methods: Between August 17, 2012 and January 25, 2013, four sites enrolled healthy adults 18–70 years of age. Subjects were randomized to receive one of the following vaccination regimens: trivalent hemagglutinin (HA) DNA prime followed by trivalent inactivated influenza vaccine (IIV3) boost with a 3.5 month interval (DNA-IIV3), IIV3 prime followed by IIV3 boost with a 10 month interval (IIV3-IIV3), or concurrent DNA and IIV3 prime followed by IIV3 boost with a 10 month interval (DNA/IIV3-IIV3). Each regimen was additionally stratified by an IIV3 administration route of either intramuscular (IM) or intradermal (ID). DNA vaccines were administered by a needle-free jet injector (Biojector). Study objectives included evaluating the safety and tolerability of each regimen and measuring the antibody response by hemagglutination inhibition (HAI). Results: Three hundred and sixteen subjects enrolled. Local reactogenicity was mild to moderate in severity, with higher frequencies recorded following DNA vaccine administered by Biojector compared to IIV3 by either route (p <0.02 for pain, swelling, and redness) and following IIV3 by ID route compared to IM route (p <0.001 for swelling and redness). Systemic reactogenicity was similar between regimens. Though no overall differences were observed between regimens, the highest titers post boost were observed in the DNA-IIV3 group by ID route and in the IIV3-IIV3 group by IM route. Conclusions: All vaccination regimens were found to be safe and tolerable. While there were no overall differences between regimens, the DNA-IIV3 group by ID route, and the IIV3-IIV3 group by IM route, showed higher responses compared to the other same-route regimens. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

443. unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Author

Yamamoto, Takuya, Masuta, Yuji, Momota, Masatoshi, Kanekiyo, Masaru, Kanuma, Tomohiro, Takahama, Shoukichi, Moriishi, Eiko, Yasutomi, Yasuhiro, Saito, Takashi, Graham, Barney S, Takahashi, Yoshimasa, and Ishii, Ken J

Subjects
VIRUS diseases, INFLUENZA A virus, INFLUENZA vaccines, VACCINES, VACCINE effectiveness
Abstract

The development of a universal influenza vaccine that can provide a robust and long-lasting protection against a broader range of influenza virus strains is a global public health priority. One approach to improve vaccine efficacy is to use an adjuvant to boost immune responses to the target antigens; nevertheless, the role of adjuvants in the context of influenza vaccines is not fully understood. We have previously developed the K3-schizophyllan (SPG) adjuvant, which is composed of nanoparticulated oligodeoxynucleotides K3, a TLR9 agonist, with SPG, a non-agonistic β-glucan ligand of Dectin-1. In this study, K3-SPG given with conventional influenza hemagglutinin (HA) split vaccine (K3-SPG HA) conferred protection against antigenically mismatched heterologous virus challenge. While K3-SPG HA elicited robust cross-reactive HA-specific IgG2c and CD8 T-cell responses, CD8 T-cell depletion had no impact on this cross-protection. In contrast, K3-SPG HA was not able to confer protection against heterologous virus challenge in FcRγ-deficient mice. Our results indicated that FcγR-mediated antibody responses induced by the HA antigen and K3-SPG adjuvant were important for potent protection against antigenically mismatched influenza virus infection. Thus, we demonstrated that the K3-SPG-adjuvanted vaccine strategy broadens protective immunity against influenza and provides a basis for the development of next-generation influenza vaccines. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

444. Modulating immunodominance hierarchy of immunoglobulin germline-encoded structural motifs targeting the influenza hemagglutinin stem

Author

Ataca, Sila, Sangesland, Maya, de Paiva Fróes Rocha, Rebeca, Torrents de la Peña, Alba, Ronsard, Larance, Boyoglu-Barnum, Seyhan, Gillespie, Rebecca A., Tsybovsky, Yaroslav, Stephens, Tyler, Moin, Syed M., Lederhofer, Julia, Creanga, Adrian, Andrews, Sarah F., Barnes, Ralston M., Rohrer, Daniel, Lonberg, Nils, Graham, Barney S., Ward, Andrew B., Lingwood, Daniel, and Kanekiyo, Masaru

Abstract

Antibodies targeting epitopes through germline-encoded motifs can be found in different individuals. While these public antibodies are often beneficial, they also pose hurdles for subdominant antibodies to emerge. Here, we use transgenic mice that reproduce the human IGHV1-69∗01 germline-encoded antibody response to the conserved stem epitope on group 1 hemagglutinin (HA) of influenza A virus to show that this germline-endowed response can be overridden by a subdominant yet cross-group reactive public antibody response. Immunization with a non-cognate group 2 HA stem enriched B cells harboring the IGHD3-9 gene, thereby switching from the IGHV1-69- to IGHD3-9-encoded motif-dependent epitope recognition. These IGHD3-9 antibodies bound, neutralized, and conferred cross-group protection in mice against influenza A viruses. A cryo-EM structure of an IGHD3-9 antibody resembled human broadly neutralizing antibody FI6v3 which uses IGHD3-9. Together, our findings offer insights into vaccine regimens that engage an immunoglobulin repertoire with broader cross-reactivity to influenza A viruses.

Published
2024
Full Text
View/download PDF

445. Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection

Author

CTI Leusen, CTI, Intensive care patientenzorg, Other research (not in main researchprogram), Infection & Immunity, Cluster D, Child Health, MMB, MMB Research line 3a, Lab exp immunologie / biomarkers ontst., CTI Bont, Infectieziekten onderzoek1 (Bont), Jacobino, Shamir R., Nederend, Maaike, Hennus, Marije, Houben, Michiel L., Ngwuta, Joan O., Viveen, Marco, Coenjaerts, Frank E.J., Hack, C. Erik, van Neerven, R. J Joost, Graham, Barney S., Bont, Louis, Leusen, Jeanette H W, CTI Leusen, CTI, Intensive care patientenzorg, Other research (not in main researchprogram), Infection & Immunity, Cluster D, Child Health, MMB, MMB Research line 3a, Lab exp immunologie / biomarkers ontst., CTI Bont, Infectieziekten onderzoek1 (Bont), Jacobino, Shamir R., Nederend, Maaike, Hennus, Marije, Houben, Michiel L., Ngwuta, Joan O., Viveen, Marco, Coenjaerts, Frank E.J., Hack, C. Erik, van Neerven, R. J Joost, Graham, Barney S., Bont, Louis, and Leusen, Jeanette H W

Published
2016

446. Extrapulmonary thoracic disease caused by Blastomyces dermatitidis

Author

Neuzil, Kathleen M., Mitchell, Holly C., Loyd, James E., Lagerstrom, Carl F., Hammon, Jr., John W., and Graham, Barney S.

Subjects
Blastomycosis -- Case studies, Health, Case studies
Abstract

A case of blastomycosis is reported involving the mediastinum and compromising the plexus brachialis. The pathology, pathophysiology, and treatment of this patient and of a previously reported patient are discussed [...]

Published
1994

447. Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

Author

Ishizuka, Andrew S, Lyke, Kirsten E, DeZure, Adam, Berry, Andrea A, Richie, Thomas L, Mendoza, Floreliz H, Enama, Mary E, Gordon, Ingelise J, Chang, Lee-Jah, Sarwar, Uzma N, Zephir, Kathryn L, Holman, LaSonji A, James, Eric R, Billingsley, Peter F, Gunasekera, Anusha, Chakravarty, Sumana, Manoj, Anita, Li, MingLin, Ruben, Adam J, Li, Tao, Eappen, Abraham G, Stafford, Richard E, K C, Natasha, Murshedkar, Tooba, DeCederfelt, Hope, Plummer, Sarah H, Hendel, Cynthia S, Novik, Laura, Costner, Pamela J M, Saunders, Jamie G, Laurens, Matthew B, Plowe, Christopher V, Flynn, Barbara, Whalen, William R, Todd, J P, Noor, Jay, Rao, Srinivas, Sierra-Davidson, Kailan, Lynn, Geoffrey M, Epstein, Judith E, Kemp, Margaret A, Fahle, Gary A, Mikolajczak, Sebastian A, Fishbaugher, Matthew, Sack, Brandon K, Kappe, Stefan H I, Davidson, Silas A, Garver, Lindsey S, Björkström, Niklas K, Nason, Martha C, Graham, Barney S, Roederer, Mario, Sim, B Kim Lee, Hoffman, Stephen L, Ledgerwood, Julie E, and Seder, Robert A

Subjects
Biological sciences, Health
Abstract

Author(s): Andrew S Ishizuka; Kirsten E Lyke; Adam DeZure; Andrea A Berry; Thomas L Richie; Floreliz H Mendoza; Mary E Enama; Ingelise J Gordon; Lee-Jah Chang; Uzma N Sarwar; Kathryn [...]

Published
2016
Full Text
View/download PDF

448. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

Author

Bar, Katharine J., primary, Sneller, Michael C., additional, Harrison, Linda J., additional, Justement, J. Shawn, additional, Overton, Edgar T., additional, Petrone, Mary E., additional, Salantes, D. Brenda, additional, Seamon, Catherine A., additional, Scheinfeld, Benjamin, additional, Kwan, Richard W., additional, Learn, Gerald H., additional, Proschan, Michael A., additional, Kreider, Edward F., additional, Blazkova, Jana, additional, Bardsley, Mark, additional, Refsland, Eric W., additional, Messer, Michael, additional, Clarridge, Katherine E., additional, Tustin, Nancy B., additional, Madden, Patrick J., additional, Oden, KaSaundra, additional, O’Dell, Sijy J., additional, Jarocki, Bernadette, additional, Shiakolas, Andrea R., additional, Tressler, Randall L., additional, Doria-Rose, Nicole A., additional, Bailer, Robert T., additional, Ledgerwood, Julie E., additional, Capparelli, Edmund V., additional, Lynch, Rebecca M., additional, Graham, Barney S., additional, Moir, Susan, additional, Koup, Richard A., additional, Mascola, John R., additional, Hoxie, James A., additional, Fauci, Anthony S., additional, Tebas, Pablo, additional, and Chun, Tae-Wook, additional

Published
2016
Full Text
View/download PDF

450. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector

Author

Liang, Bo, primary, Ngwuta, Joan O., additional, Herbert, Richard, additional, Swerczek, Joanna, additional, Dorward, David W., additional, Amaro-Carambot, Emerito, additional, Mackow, Natalie, additional, Kabatova, Barbora, additional, Lingemann, Matthias, additional, Surman, Sonja, additional, Yang, Lijuan, additional, Chen, Man, additional, Moin, Syed M., additional, Kumar, Azad, additional, McLellan, Jason S., additional, Kwong, Peter D., additional, Graham, Barney S., additional, Schaap-Nutt, Anne, additional, Collins, Peter L., additional, and Munir, Shirin, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results